Not Signed In - DURECT Starts Phase II Dosing For TRANSDUR(TM)-Bupivacaine (DUR-843)
Fri, 05 Jan 2007 08:00 AM EST
... DURECT Corporation (Nasdaq: DRRX) today announced that we have started Phase II dosing in the U.S. under an FDA-accepted Investigational New Drug (IND) application for TRANSDUR(TM)-Bupivacaine (DUR-843), a transdermal pain patch for patients suffering from Post-Herpetic Neuralgia (post-shingles pain or PHN). [click link for full article] ...
Related Topics
- Theophylline ER
- Nitroglycerin Skin Patches
- Bupivacaine injection
- Clinical Trials
- Bupivacaine
- Nystatin and Triamcinolone
- Bupivacaine and Lidocaine injection
- Food Recommendations: South Beach Diet - Phase 2
- Food Recommendations: South Beach Diet - Phase 1
- Potassium Chloride Oral
- Kniest dysplasia
- Juvenile Diabetes
- Membranoproliferative GN II
- Factor II deficiency
- Phenylephrine and Guaifenesin Capsules
- Pena Shokeir II Syndrome
- Cockayne Syndrome Type II
- Carboplatin
- Ramsay Hunt Syndrome Type II
- Multiple endocrine neoplasia (MEN) II
email this page
print this page
bookmark this page
feedback on this page
